- Home
- CRDL vs PLX Comparison
CRDL vs PLX Comparison
Compare CRDL & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDL
- PLX
- Stock Information
- Founded
- CRDL 2017
- PLX 1993
- Country
- CRDL Canada
- PLX United States
- Employees
- CRDL N/A
- PLX N/A
- Industry
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CRDL Health Care
- PLX Health Care
- Exchange
- CRDL Nasdaq
- PLX Nasdaq
- Market Cap
- CRDL 126.5M
- PLX 127.4M
- IPO Year
- CRDL N/A
- PLX 1998
- Fundamental
- Price
- CRDL $1.48
- PLX $1.49
- Analyst Decision
- CRDL Strong Buy
- PLX Strong Buy
- Analyst Count
- CRDL 2
- PLX 1
- Target Price
- CRDL $9.00
- PLX $15.00
- AVG Volume (30 Days)
- CRDL 365.4K
- PLX 616.7K
- Earning Date
- CRDL 08-11-2025
- PLX 08-13-2025
- Dividend Yield
- CRDL N/A
- PLX N/A
- EPS Growth
- CRDL N/A
- PLX N/A
- EPS
- CRDL N/A
- PLX 0.05
- Revenue
- CRDL N/A
- PLX $59,764,000.00
- Revenue This Year
- CRDL N/A
- PLX $65.02
- Revenue Next Year
- CRDL N/A
- PLX $57.34
- P/E Ratio
- CRDL N/A
- PLX $31.04
- Revenue Growth
- CRDL N/A
- PLX 0.18
- 52 Week Low
- CRDL $0.77
- PLX $0.82
- 52 Week High
- CRDL $2.63
- PLX $3.10
- Technical
- Relative Strength Index (RSI)
- CRDL 57.55
- PLX 47.81
- Support Level
- CRDL $1.36
- PLX $1.46
- Resistance Level
- CRDL $1.59
- PLX $1.53
- Average True Range (ATR)
- CRDL 0.11
- PLX 0.06
- MACD
- CRDL 0.02
- PLX 0.01
- Stochastic Oscillator
- CRDL 75.56
- PLX 46.43
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.